That Anavex claims the 148 week data "Confirms Role of Patient Selection Biomarkers" is in my opinion very significant.
That is if we take the genetic findings and all the science and methods like KEM as factually correct, then the certainty that confirmatory trials will do just that is very high.
If at least some competitors and investors big and small read into this what it says, then they would want to own some or all of it.
The abstract title reads very strong in the context of all prior Anavex knowledge (yes I know many will be very critical and rightly so), thus I am not quite sure what else Anavex have up their sleeve that can't appear on clinical trial sites just yet.
Guesses could be around some kind of licensing/partnering deal to be revealed post CTAD...
Ok wait for all the usual posts shooting this down based on incompetent management and too favourably presented data.
News 
Market Data 
Discover 
AI
